NCT03724942View on ClinicalTrials.gov

Brexpiprazole for the Long-term Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type

PHASE3CompletedINTERVENTIONAL
Enrollment

164

Participants

Timeline

Start Date

November 9, 2018

Primary Completion Date

December 2, 2021

Study Completion Date

January 5, 2022

Conditions
Agitation Associated With Dementia of the Alzheimer's Type
Interventions
DRUG

Brexpiprazole

Brexpiprazole 1mg or 2mg will be orally once daily for 14 weeks

Trial Locations (1)

Unknown

Jisenkai Nanko Psychiatric Institute, Shirakawa

Sponsors
All Listed Sponsors
lead

Otsuka Pharmaceutical Co., Ltd.

INDUSTRY